Bio-Rad Laboratories Class A
400 hedge funds and large institutions have $5.7B invested in Bio-Rad Laboratories Class A in 2026 Q2 according to their latest regulatory filings, with 60 funds opening new positions, 113 increasing their positions, 156 reducing their positions, and 52 closing their positions.
753% more call options, than puts
Call options by funds: $15M | Put options by funds: $1.76M
15% more first-time investments, than exits
New positions opened: 60 | Existing positions closed: 52
1% more funds holding
Funds holding: 395 → 400 (+5)
2% more capital invested
Capital invested by funds: $5.57B → $5.7B (+$127M)
1.76% less ownership
Funds ownership: 91.2% → 89.44% (-1.8%)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
28% less repeat investments, than reductions
Existing positions increased: 113 | Existing positions reduced: 156
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$36.4M |
| 2 |
Nomura Holdings
Tokyo,
Japan
|
+$31.6M |
| 3 |
Neuberger Berman Group
New York
|
+$30.9M |
| 4 |
SG Americas Securities
New York
|
+$29.4M |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
+$29.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$110M |
| 2 |
Parnassus Investments
San Francisco,
California
|
-$70.9M |
| 3 |
SAM
Southeastern Asset Management
Memphis,
Tennessee
|
-$45.4M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$41.1M |
| 5 |
CBU
CIBC Bancorp USA
Chicago,
Illinois
|
-$33.5M |
BIO Hedge Fund Activity: Q2 2026 in Review
400 of the 8,349 institutional investors tracked by Wall St. Rank reported a position in Bio-Rad Laboratories Class A (BIO) for Q2 2026, worth a combined $5.7B — up 2.3% from $5.57B a quarter earlier.
Buyers outnumbered sellers: 60 funds opened new BIO positions and 52 closed out — a net gain of 8 holders — while 113 added to existing stakes and 156 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $36.4M. The largest seller was Massachusetts Financial Services, cutting an estimated $110M.
- 400 institutional investors held Bio-Rad Laboratories Class A (BIO) as of Q2 2026, up from 395 in Q1 2026.
- Funds reported $5.7B of Bio-Rad Laboratories Class A stock for Q2 2026, up 2.3% quarter-over-quarter.
- 60 funds opened new Bio-Rad Laboratories Class A positions in Q2 2026 and 52 closed out, a net change of +8 holders.
- The largest Bio-Rad Laboratories Class A buyer in Q2 2026 was Goldman Sachs, an estimated $36.4M added.
- The largest Bio-Rad Laboratories Class A seller in Q2 2026 was Massachusetts Financial Services, an estimated $110M sold.
Based on aggregated 13F filings for Q2 2026.